How to Screen ADC Nanobodies for Tumor Selectivity

To screen ADC nanobodies for tumor selectivity, compare binding, internalization, and payload-dependent killing in antigen-positive tumor models against relevant antigen-positive normal cells. Start by confirming target expression and nanobody specificity, then test uptake and cytotoxicity with matched controls. For veterinary medicine, use cells and tissues from the intended animal species whenever possible: a nanobody’s performance on human cells does not establish its binding to canine, feline, or other veterinary targets. No single assay proves selectivity, so advance candidates only when results are consistent across complementary models and the intended species.

Click here to get more.

Key takeaways

• Define tumor selectivity as a comparison with relevant normal tissues, not simply strong binding to a tumor cell line.
• Screen target expression, nanobody binding, internalization, and ADC-mediated activity as separate but connected questions.
• Use matched antigen-negative controls, nonbinding nanobody controls, and payload or linker controls to interpret results.
• Set project-specific advancement criteria before testing; there is no universal selectivity ratio that guarantees safety or efficacy.

What tumor selectivity means for an ADC nanobody

An ADC nanobody combines a target-binding domain with a linker and cytotoxic payload. Its intended advantage is to deliver more payload to target-expressing tumor cells than to cells in normal tissues. In practice, selectivity depends on several factors, including antigen abundance and accessibility, binding specificity, internalization, linker stability, payload sensitivity, and exposure in the organism.

For that reason, high-affinity binding alone is not a sufficient selection criterion. A candidate can bind a tumor cell strongly yet also recognize normal tissue, fail to internalize, or show little difference in payload-dependent activity between tumor and normal models. Screening should therefore progress from target biology to functional testing, with each stage designed to rule out a different source of risk.

Step-by-step screening workflow

1. Define the indication, species, and target

Before comparing candidates, specify the tumor type, intended veterinary species, target antigen, and available model systems. Review whether the target is reported or observed in relevant normal tissues, and identify any known species differences in the target sequence or expression pattern. This context determines which cells are informative and whether a candidate that binds a human target is relevant to a veterinary program.

Include normal-cell types that represent plausible exposure risks for the intended indication. When primary cells or tissue-derived models are available, they can complement engineered cell lines, although availability and donor variability may limit direct comparisons. Record the source, species, passage history, and target-expression method for every model.

2. Confirm target expression and binding specificity

Measure target expression in tumor and normal models using a suitable method, such as flow cytometry, immunostaining, or a validated protein assay. Test nanobody binding across antigen-positive and antigen-negative cells, and include an irrelevant or nonbinding nanobody as a negative control. Where possible, use a target knockout or knockdown model to check whether binding depends on the intended antigen.

Compare binding across a concentration range rather than relying on one concentration. A 4°C binding incubation can be used as a starting condition to reduce active internalization during surface-binding measurements, but the protocol should be optimized for the cell type and assay. Report the assay format and conditions alongside any apparent affinity or signal comparison; results from different formats are not automatically interchangeable.

3. Test internalization and intracellular delivery

For an ADC, surface recognition must be followed by productive delivery when the design depends on internalization. Use a validated uptake assay, such as labeled nanobody tracking or a suitable imaging or flow-cytometry method, and distinguish surface-bound material from internalized material where the assay permits. Compare tumor and normal cells under matched conditions, while checking that labeling has not materially changed binding.

Internalization is a useful selection attribute, not a stand-alone proof of ADC performance. Trafficking and payload release can differ between cell types, and some ADC designs may rely on mechanisms beyond rapid internalization. Interpret uptake together with functional activity and the linker-payload design.

4. Compare ADC activity with appropriate controls

Test the conjugated candidate against tumor and normal models, then compare its activity with unconjugated nanobody, free payload where appropriate, and a nonbinding ADC control. Include antigen-negative cells to assess target-independent effects. A cell-viability experiment may use a 24–72-hour exposure as an initial planning window, but exposure time and readout must be optimized for the payload, cell growth rate, and assay format.

NBbiolab supply professional and honest service.

Look for a consistent difference in response between relevant tumor and normal models, not merely a low viability value in one tumor line. Use dose-response curves and report the assay’s replicate structure and variability. The number of replicates should be chosen for the study design and statistical plan; it should not be presented as a universal threshold for candidate acceptance.

5. Confirm performance in more representative models

Advance promising candidates into additional models that address limitations of simple cell lines. Depending on project scope, these may include primary cells, co-cultures, organoids, or three-dimensional tumor models. Such systems can add context about cell organization and accessibility, but they do not replace species-relevant normal-tissue assessment or in vivo evaluation when justified.

For veterinary development, assess whether the candidate cross-reacts with the intended species’ target and relevant normal tissues. If a surrogate species or cross-reactive molecule is used, document the rationale and limitations. A lack of binding in one species may reflect sequence differences rather than favorable tumor selectivity.

Key decision points for candidate advancement

Separate target selectivity from payload sensitivity

A tumor model may appear more susceptible because it is intrinsically more sensitive to a payload, even when nanobody targeting is not selective. Compare free-payload responses and nonbinding ADC activity to identify this possibility. The strongest interpretation comes from converging evidence: antigen-dependent binding, appropriate uptake or delivery, and a functional difference that is reduced or lost when the target is absent.

Use a project-defined selectivity framework

Summarize tumor-versus-normal results using clearly defined measures, such as normalized binding signal or differences in concentration-response behavior. State how each metric is calculated and which cell models it includes. Avoid treating a single ratio or cutoff as a universal safety benchmark, because assay conditions, target biology, species, and payload mechanism all affect interpretation.

Consider conjugate quality and reproducibility

Functional screening can be misleading if conjugate composition or sample handling varies between candidates. Track relevant analytical information, including identity, purity, aggregation, and conjugation characteristics where applicable. Confirm that test materials are comparable before attributing differences in activity to the nanobody sequence.

Common screening mistakes and how to avoid them

• Using tumor cells alone: Include relevant normal cells and antigen-negative controls to assess selectivity and target dependence.
• Ranking by binding strength only: Add internalization and conjugate activity assays before nominating a lead.
• Ignoring species differences: Confirm target recognition in the intended veterinary species and explain any surrogate-model limitations.
• Confounding targeting with payload toxicity: Compare free payload and nonbinding ADC controls alongside the targeted conjugate.
• Applying one assay cutoff to every project: Set advancement rules based on the indication, models, and evidence quality, and document them before reviewing candidate rankings.

How NBbiolab can support an ADC nanobody screening plan

At NBbiolab, we can discuss project requirements for ADC target nanobody discovery and help buyers define a screening scope around target, species, tumor indication, and available models. A practical request for proposal should specify the target sequence or species, desired binding and functional assays, control materials, sample format, and expected deliverables. Buyers should also clarify whether the requested work covers discovery only or extends to conjugation, analytical characterization, and functional evaluation.

Before commissioning a screen, ask how candidates will be compared, how normal-cell models will be selected, and how species cross-reactivity will be reported. Request the assay methods, controls, and limitations in the study plan so results can inform a clear next decision. The precise scope, timeline, and material requirements depend on the project design and should be confirmed directly with the supplier.

Conclusion

The most reliable way to screen ADC nanobodies for tumor selectivity is to build evidence in stages: confirm target expression and species relevance, measure antigen-dependent binding, evaluate delivery or internalization, and compare ADC activity in tumor and relevant normal models with appropriate controls. For veterinary programs, species-matched target and tissue assessment is essential to interpreting the results. Define project-specific advancement criteria before testing, then use the findings to decide which candidates warrant broader model evaluation; NBbiolab can discuss a discovery and screening scope aligned with those requirements.